Superior Planning, LLC’s First Tracks Biotherapeutics TRAX Stock Holding History

Superior Planning, LLC’s Portfolio TRAX Stock Details TRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$7.58K	Buy	+214	New	+$8.36K	﹤0.01%	1039

Other funds holding TRAX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $60.6B AUM 33.98% 1-Year Est. Return

Superior Planning, LLC's TRAX Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in First Tracks Biotherapeutics (TRAX) in Q3 2026: 214 shares worth $7.58K. The stake represents ﹤0.01% of the portfolio and ranks #1039 among its holdings.

89 funds tracked by Wall St. Rank hold TRAX as of Q3 2026.

Superior Planning, LLC held 214 shares of First Tracks Biotherapeutics worth $7.58K as of Q3 2026.
First Tracks Biotherapeutics was a new Superior Planning, LLC position in Q3 2026.
First Tracks Biotherapeutics made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #1039 holding.
89 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.